Iris Energy Free cash flow decreased by 86.7% to -$873.83M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1601.8%, from -$51.35M to -$873.83M. Over 2 years (FY 2023 to FY 2025), Free cash flow shows a downward trend with a 72.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$27.58M | -$27.58M | -$27.58M | -$27.58M | -$22.41M | -$22.41M | -$22.41M | -$22.41M | -$109.75M | -$85.50M | -$51.35M | -$80.97M | -$37.95M | -$468.04M | -$873.83M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +18.8% | +0.0% | +0.0% | +0.0% | -389.7% | +22.1% | +39.9% | -57.7% | +53.1% | <-999% | -86.7% |
| YoY Change | — | — | — | — | +18.8% | +18.8% | +18.8% | +18.8% | -389.7% | -281.6% | -129.1% | -261.3% | +65.4% | -447.4% | <-999% |